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Abstract
The primary objective of this study was to evaluate the safety and the effect of D-tagatose on the
glycemic control of subjects with type 2 diabetes as determined by HbA1c levels at the end of 6 months of
therapy using the subject’s own baseline HbA1c level as a comparator. The determination of the minimal dose
required to cause a statistically significant reduction in HbA1c was of particular interest. Eight weeks after
screening, the qualifying subjects were randomized to receive one of three doses of D-tagatose: 2.5 g TID,
5.0 g TID or 7.5 g TID. Blood levels of HbA1c, fasting blood glucose concentrations, plasma lipids, changes in
body weight, changes in body mass index, and change in insulin levels were checked at each study visit and
at the end of the study. Treatment success, as measured by the reduction of HbA1c, was greatest for the 7.5 g
D-tagatose dose group, although the difference between the treatments was not statistically significant. For
fasting glucose, only the 7.5 g dosage group exhibited reductions from baseline at the 3- and 6-month time
points. Mean body weights reduced in a dose-response fashion, with the 5.0 g and the 7.5 g D-tagatose
doses providing the greatest reductions. D-tagatose at dosages of 2.5 g, 5.0 g, and 7.5 g TID for six months
were well tolerated by this subject population. D-tagatose at 5.0 g TID was the minimal dose required to
reduce HbA1c. D-tagatose at 7.5 g TID provided the greatest effect in most measured efficacy parameters.

ABBREVIATIONS
AE - Adverse event; EE - Efficacy evaluable; GRAS - Generally
recognized as safe; HbA1c - Glycosylated hemoglobin A1c; HDL High-density lipoprotein; ITT - Intent-to-treat; LDL - Low density
lipoprotein; SAE - Serious adverse event; TID - three times daily;
VLDL - Very low density lipoprotein.

INTRODUCTION

Peripheral insulin resistance and progressive failure
of pancreatic β-cell function leading to inadequate insulin
secretion are the two principal abnormalities that characterize
the pathogenesis of type 2 diabetes [1]. Early intervention at
the onset of type 2 diabetes generally consists of maintaining a
proper diet and weight, along with regular exercise. If control
of blood glucose deteriorates further, then pharmacological
intervention with one or more oral anti-diabetic agents is

required. Unfortunately for many, type 2 diabetes will continue
to progress and exogenous insulin treatment as primary therapy
with oral anti-diabetic agents as adjunctive therapy are required
in order to achieve glycemic control. Treatment with insulin
is usually a point of no return for these patients and a major
treatment goal is to prevent progression to this point. Despite all
of these interventions including insulin and the introduction of
a number of novel agents for the treatment of type 2 diabetes in
recent years, glucose control for many remains unsatisfactory.
Recently, a review that included 140 controlled trials and 26
observational studies comparing diabetes medications, both as
monotherapy and in two-drug combinations, concluded that there
was not enough evidence to clearly support the use of one drug or
drug combination over another for stemming the complications
of diabetes, including macrovascular and microvascular
complications and mortality [2]. Metformin, a drug introduced in
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the United States in 1994 and as early as 1958 in other countries,
is still the most common first drug of choice for the treatment of
type 2 diabetes. Compared to the newer drugs, metformin is the
drug that has the highest benefit-to-risk ratio for intermediate
outcomes, such as HbA1c reduction, less weight gain and less risk
of hypoglycemia. However, no currently available therapy has
been shown to slow the decline in β-cell function in established
type 2 diabetes. Even with aggressive intervention, it is estimated
that 60% of diabetics don’t achieve target blood sugar levels with
their current treatment [3]. Moreover, particular drugs available
for treatment of diabetes may result in unwanted weight gain
(long and rapid acting insulin, sulfonylureas, thiazolidinediones,
repaglinide, nateglinide), hypoglycemia (insulin, sulfonylureas),
gastrointestinal distress (metformin, α-glucosidase inhibitor,
amylin mimetics, bile acid sequestrant, bromocriptine), or more
serious adverse events such as pancreatitis (short and longacting glucagon-like peptide-1(GLP-1) agonists and dipeptidyl
peptidase-4 (DDP-4) inhibitors) [4,5]. These findings illustrate
the limitations of drug therapies currently available for the
progression of diabetes.

The observation that many diabetics are not able to consistently control their blood sugar levels within recommended
limits using the best available treatments, uncovers the serious
need for a drug that can slow and/or halt the progression of diabetes. Preferably, such a drug should exhibit a unique mode of
action to enable additive or synergistic use with current therapies; produce no weight gain, hypoglycemia, or other limiting or
unmanageable side effects; preserve or enhance β-cell function;
and reduce cardiovascular risk factors that lead to morbidity and
mortality.

D-tagatose is an isomer of fructose and is ~90% as sweet as
sucrose, or sugar. D-tagatose was designated in 2001 as a Generally Recognized as Safe (GRAS) product by the United States Food
and Drug Administration and is used as a nutritive or low-calorie
sweetener [6,7]. Currently, D-tagatose may be used as a sweetener in diet beverages, light ice creams or yogurts, and regular or
dietetic hard candies [Rulis Agency response letter GRAS notice].
Preliminary animal and pre-clinical studies of D-tagatose have
demonstrated its ability to lower blood glucose and lipoprotein
levels. When consumed, D-tagatose functions as a “sugar blocker”
by inhibiting lipid formation from carbohydrates without stimulation of pancreatic beta cells for insulin production or secretion
[7]. Regarding lipoprotein levels, D-tagatose has been shown to
reduce total cholesterol and VLDL and LDL-cholesterol when
compared to sucrose [8], and increase HDL-cholesterol levels
[9]. A number of clinical trials demonstrating the ability of Dtagatose to blunt postprandial rises in blood glucose and reduce
HbA1c have been conducted on healthy subjects and diabetic patients [10-16]. Single-dose and repeated-dose studies in healthy
and diabetic human subjects have shown that the predominant
adverse effects associated with excessive consumption of Dtagatose are gastrointestinal disturbances attributed to osmotic
effects from incompletely absorbed D-tagatose [10-16]. Such
effects are also commonly associated with excessive consumption of other poorly digestible carbohydrates including polyols.
Therefore, D-tagatose shows promise in multiple clinical applications, including the treatment of diabetes. In short, D-tagatose
provides glycemic and lipoprotein control through a mechanism
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

of action unlike any agent that is currently available on the market in the United States.

The primary objective of this study was to evaluate the effect of three low-doses of D-tagatose on the glycemic control of
subjects with type 2 diabetes. The purpose was to determine the
minimum dose able to reduce HbA1c. The secondary objectives
were to evaluate the effect of these three doses of D-tagatose
compared to the subject’s own baseline levels for
•• HbA1c at each study visit
•• fasting plasma glucose
•• fasting lipid profiles

•• insulin concentration

•• changes in body weight

•• the number of subjects requiring additional anti-diabetic
medications and/or withdrawal from the study due to
high glycemic measurements

In addition, the safety of D-tagatose in regards to hypoglycemic episodes, gastrointestinal side effects, other adverse events,
clinical laboratory abnormalities, and physical examinations was
evaluated.

SUBJECTS AND METHODS
Ethics

The protocol was reviewed and approved by an Institutional
Review Board (IRB) before the study was initiated. This trial
was conducted in accordance with regulations governing clinical
trials including the US Code of Federal Regulations (CFR), Title
21, Part 50; regulations governing IRBs, Title 21, Part 56; and the
Declaration of Helsinki concerning medical research in humans.
Additional governing regulations included US CFR Title 21, Part 54
and US CFR Title 21, Part 312. This study was also conducted
according to International Conference on Harmonization (ICH)
Good Clinical Practices (GCP).

Subject information and consent

Prior to entry into the study, the nature and risks of the study
were reviewed with each subject. Each subject or each subject’s
legal representative was given the opportunity to read the IRBapproved consent form and to ask questions.

Criteria for evaluation

The populations analyzed for efficacy endpoints were the
intent-to-treat (ITT) population and the efficacy evaluable (EE)
population. The population used to analyze safety parameters
was identical to the ITT population. Analysis of demographic
and baseline for the ITT, EE and Safety populations indicated
no gross dissimilarities between the three D-tagatose dose
groups. The majority of subjects in each of the treatment groups
and populations were male, Asian, non-smoking, non-drinking,
around 50 years of age, weighing approximately 150 lbs, with
diet and exercise for control of their diabetes. Usage of allowable
medications during the trial was also similar across the three
treatment groups.
Primary Efficacy Endpoint: The primary endpoint for this
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Phase 2 dose-ranging study was a decrease of ≥ 0.5% in HbA1c
level after 6 months of the study treatment.

Secondary Efficacy Endpoints: Secondary endpoints for this
study included assessment of the effects of D-tagatose on other
glycemic control measurements. These measurements included
the proportions of subjects at each visit who achieved a decrease
in HbA1c of ≥ 0.5%; proportions of subjects at each visit who
achieved a decrease in HbA1c level of ≥ 1%; change from baseline
to each study visit in fasting blood glucose concentrations,
and plasma lipids (triglycerides, low density lipoprotein, total
cholesterol, and high density lipoprotein); changes in body
weight; changes in body mass index; and change in insulin levels.

Safety: Descriptive statistics and by-subject data listings
were prepared for all safety parameters. No inferential statistics
were performed for safety parameters. Safety was assessed
through the entire duration of the study, and in the event of an
adverse event (AE) or serious adverse event (SAE), safety was to
be monitored until the AE/SAE resolved, or until the AE/SAE was
deemed chronic or stable by the investigator.

Study design and plan

This study was designed as a prospective, randomized,
6-month, parallel dose-ranging trial in subjects with mild type
2 diabetes who, at the time of randomization, were not taking
any oral anti-diabetic or anti-hyperglycemic medication or
parenteral anti-diabetic medication and were controlling their
diabetes with diet and exercise alone. This Phase 2 parallel doseranging trial was designed to evaluate the dose-response effect
of minimal doses of D-tagatose (2.5, 5.0, or 7.5 g,TID) on glycemic
control in subjects with type 2 diabetes, who had undergone an
8-week run-in period of standardized diet and exercise. This
8-week stabilization period was considered a sufficient duration
of standardized diet and exercise to provide a homogenous
population of subjects with type 2 diabetes. No active control
group was utilized in the design as the study was intended as a
dose-ranging trial. The data from this trial was not intended to
provide evidence of equivalence or superiority to any currently
marketed medication.

A total of 112 subjects were planned to be randomized into
the study (i.e., 34 subjects to each of three treatment groups:
2.5 g, 5.0 g, and 7.5 g D-tagatose given orally, three times daily,
immediately prior to meals). Eight weeks after screening and
stabilization, qualified subjects were randomized to receive
one of three doses of D-tagatose. All doses of D-tagatose were
premixed with drinking water into a solution of 4 ounces per
dose. The study design is depicted in Figure 1.

At the initial visit (Visit 1) subjects were screened for
eligibility for entering the study. Subjects who were eligible were
those diabetic subjects treated solely with diet and exercise and
who had mildly elevated HbA1c levels but were otherwise in good
health and were not suffering from any serious complications
of diabetes or any other significant concurrent disease. Subjects
were not to be taking any medications for the treatment of
type 2 diabetes. The screening visit consisted of each subject
undergoing a review of their relevant medical history and a
physical examination, both of these primarily aimed at finding any
abnormalities related to complications of diabetes. Additionally,
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

Figure 1 Study Schedule. Subjects underwent an 8-week run-in
period of standardized diet and exercise to provide a homogenous
population of subjects with type 2 diabetes prior to randomization
into three treatment groups. Treatment lasted for 6 months. Total
duration of the study for subjects was 24 weeks with five study visits
during the trial.

clinical laboratory testing (including comprehensive hematology,
clinical chemistry, liver function tests, lipid profile, HbA1c levels
and urinalysis) was performed. At the end of the screening visit,
potentially eligible study subjects were instructed to follow a
weight-maintaining diet and a daily exercise program under the
supervision of the investigator. They were given a blank subject
diary and a nutritional diary, and were scheduled for the second
visit (Visit 2) after 8 weeks of stabilization. No study drug was
distributed at the screening visit (Visit 1).

All subjects who were eligible were randomized during Visit
2 which took place within 8 weeks (± 7 days) of Visit 1. This was a
single-blind study, in which subjects were blinded to dose group.
At Visit 2, prior to randomization, baseline procedures including
a complete medical evaluation with a review of medical history
changes since Visit 1 and a physical examination were performed
on qualifying subjects. In addition, subjects had blood drawn for
clinical laboratory testing and urinalysis.

Randomization was stratified by site and baseline HbA1c
levels (< 7.5% or ≥ 7.5%) to obtain a balanced distribution
of subjects across the three arms of the trial. In addition to a
supply of study medication, subjects received a diary and diary
completion instructions for recording side effects, intercurrent
illnesses/symptoms, and concomitant medications.
For Visits 3 and 4, subjects returned to the clinic for diary
assessment, blood tests, and study drug compliance assessment
and dispensation of additional study drug. Each of these visits
had a ± 7 day window. Subjects had blood drawn for clinical
laboratory testing and urinalysis.

During the final visit (Visit 5), the diary and all used and
unused medication packets were collected and all assessments
conducted at Visits 3 and 4 were repeated. Additionally, a final
physical examination was conducted. Subjects were instructed to
return to their primary physician for subsequent diabetes care
and follow-up. This visit had a ± 7 day window. The efficacy and
safety measurements that were evaluated throughout the study
are provided in the study schedule (Table 1).
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Table 1: Schedule of Events.

Visit 1 Screening

Subject Registration to Study

X

Informed Consent*

X

Medical History/Update

Visit 2
Randomization

Inclusion and Exclusion Criteria

X

Physical Examination

X

X

X

X

Record Concomitant Medications

X

Hematology Panel

Record Adverse Events

Visit 3
Month 1

Visit 4
Month 3

X

X

Visit 5
End of Study

X
X

X

X

X

X

X

X

X

X

X

X

X

X

X

Chemistry Panel†

X

X

X

X

X

Liver Function Tests‡

X

X

X

X

X

Lipid Profile§

X

X

X

X

X

HbA1c levels

X

X

X

X

X

Urinalysis Panel

X

X

X

X

X

X

X

X

Dispense diaries

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

Dispense Study Drug
Compensation

Collect empty study drug vials/packages
Collect completed subject diaries

X

* Explained to and signed by subject
† SMA-18 (or equivalent), creatinine clearance, and insulin levels
‡ Alanine transaminase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, total protein, and albumin
§ Total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and triglycerides

In the event a subject was discontinued for any reason, an
attempt was to be made to keep the subject on the safety arm
of the study. Study treatment for discontinued subjects was to
be stopped but the subject was to continue with the protocol
assigned study visits but not the interim study drug supply visits.
In the event the subject declined participation in the safety arm
of the trial, after treatment discontinuation, Visit 5 (the End of
Study Visit) was to be scheduled at least 30 days after the last
dose.

Clinical Samples

Blood samples used to assay HbA1c, blood glucose, insulin
concentrations and lipids (total cholesterol, triglycerides, HDL,
and LDL) were taken at each study visit, including the screening
visit prior to the run-in period. All samples were collected and
processed at the study center and then forwarded to the central
laboratory (ICON Central Laboratories, Inc., Farmingdale, NY), by
overnight courier, for assay.

Statistical Method

Three analysis populations were evaluated:

Intent-to-Treat (ITT) Population: The main efficacy analysis
was conducted using the ITT Population. The ITT population
included all subjects who had signed the study Informed Consent
Form, received the protocol-specified treatment, and had a
baseline and at least one post-baseline HbA1c value.

Efficacy Evaluable (EE) Population: The EE population was
used for supportive analyses. The EE population consisted of all
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

randomized subjects who completed treatment periods, received
at least 80% of the study medication, and had no major protocol
violations or eligibility violations. All protocol violations were to
be identified prior to database lock.

Safety Population: The safety population was used for the
analysis of safety variables. The safety population consisted of
all randomized subjects who received at least one dose of study
medication and had at least one post treatment visit of safety
assessment.

Determination of Sample Size

The sample size calculation was based on a reduction of at
least 0.5% in HbA1c level after 6 months of the study treatment
compared to baseline for each dose group, a standard deviation
of 1.0 for each treatment group, and an 80% statistical power
with a two-sided analysis at a Type I error rate of 0.05. The
required number of evaluable subjects was about 102 (34 for
each D-tagatose dose group) based on nQuery Advisor, version
6.01. A total of 40 subjects per treatment group (120 subjects for
the study) were to be recruited, as it was expected to observe a
15% drop out rate in this study population, and a total of 150
subjects (50 for per treatment group) was screened based on the
estimated screen failure rate of 20%.
Descriptive statistics and by-subject data listings were
prepared for all efficacy parameters. For continuous data,
summaries included number of observations, mean, standard
deviation, median, minimum, and maximum values. For
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categorical data, summaries included frequency counts and
percentages. All statistical tests used in efficacy assessments
were 2-sided, with no p-value adjustment. Data are presented as
the mean ± standard deviation.

The primary efficacy variable was change in HbA1c level from
baseline to 6 months. Baseline was defined as the last value
obtained prior to the first randomized treatment. Changes from
baseline HbA1c level were assessed using the general linear model
(ANCOVA) to adjust for baseline differences and the stratification
factor. Factors in the model included treatment and stratum of
baseline HbA1c (< 7.5% or ≥ 7.5%). The least square means and
standard error were derived from the general linear model for
each dose group.

For secondary efficacy endpoints, (1) logistic regression was
used to investigate the effect of treatment on the endpoint (i.e.,
decrease of ≥ 0.5% HbA1c reduction at each visit) and, decrease of
≥ 0.5% HbA1c reduction at each visit, and (2) analysis of covariance
(with stratification factor as covariate) was used to compare
changes from baseline in fasting blood glucose, triglycerides, low
density lipoprotein, total cholesterol, high density lipoprotein,
body weight, body mass index, and insulin level.

significant for either of the analysis populations (p > 0.05, logistic
regression).

Incidence of ≥ 0.5 HbA1c decrease after one, three and
six months of treatment: Incidence summaries of ≥ 0.5 HbA1c
reduction from baseline after one, three, and six months of
treatment for each of the D-tagatose dose groups are provided
in Table 2 for the ITT population and in Table 3 for the EE
population. Only the 7.5 g D-tagatose dose group indicated
a dose-response trend over time; i.e., for the ITT population,
treatment success was indicated for 4/47 (8%) after one month
of treatment, for 5/47 (11%) after three months of treatment,
and 12/47 (25%) after six months of treatment. For the EE
population, success was indicated for 2/27 (7%) at the one and
three month treatment time points and for 9/27 (33%) subjects
at the six month time point. By logistic regression, the incidences
across the three treatments at a single time point were not
statistically significantly different.
Effect of D-tagatose on HbA1c values: The mean HbA1c

RESULTS          

Study Population
The study evaluated the data from 18 clinical study sites (11
sites in the United States and 7 sites in India) and 161 subjects
were randomized to one of the three D-tagatose dosages (2.5 g:
n = 57, 5.0 g: n = 51, and 7.5 g: n = 53). Of the 161 randomized
subjects, 60 (37%) were withdrawn before completing the
6-month treatment period. The most common reasons for
withdrawal were subject request (18/161, 11%) and subject
lost to follow up (11/161, 7%). The populations analyzed for
efficacy endpoints were the ITT population (145 total; 52 in the
2.5 g treatment group, 46 in the 5.0 g treatment group and 47 in
the 7.5 g treatment group) and the EE population (87 total, 31 in
the 2.5 g treatment group, 29 in the 5.0 g treatment group, and
27 in the 7.5 g treatment group). The population used to analyze
safety parameters was identical to the ITT population. There
were no indicators of dissimilarity between the treatments in any
of the analysis populations in terms of demographic or baseline
characteristics, concomitant medication usage, or compliance
with treatment, diet, or exercise.

Efficacy Results

Incidence of ≥ 0.5 HbA1c decrease after six months of
treatment: Treatment success, as measured by the incidence of
a 0.5 minimum HbA1c decrease from baseline after six months of
treatment, was greatest for the 7.5 g TID dose of D-tagatose in
both the ITT (25%, 12/47) and the EE (33%, 9/27) populations
(see Figure 2). Treatment success, as measured by the primary
endpoint (a reduction from baseline of 0.5 in HbA1c after six
months of treatment) was greatest for the 7.5 g D-tagatose dose
group, although the difference between the treatments was not
statistically significant. For the 7.5 g dose group 25% of the
population achieved this treatment success parameter compared
to 19% in the 2.5 g dose group and 15% in the 5.0 g dose group.
The difference across the three dose groups was not statistically
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

Figure 2 Incidence of ≥ 0.5 HbA1c decrease after six months of
treatment, ITT and EE populations. ANCOVA with baseline as
covariate).

Table 2: Incidence of ≥ 0.5 HbA1c decrease from baseline after one, three
and six months of treatment, ITT population.
D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g

Treatment
Duration

One Month

Three Months

Six Months

N = 51
n (%)

8 (15.38%)

11 (21.15%)

10 (19.23%)

N = denominator for all percentages

N = 46
n (%)

9 (19.57%)

8 (17.39%)

7 (15.22%)

N = 47
n (%)

4 (8.51%)

5 (10.64%)

12 (25.53%)

Table 3: Incidence of ≥ 0.5 HbA1c decrease from baseline after one, three
and six months of treatment, EE population.
D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g

Treatment
Duration

N = 31
n (%)

N = 29
n (%)

N = 27
n (%)

One Month

6 (19.35%)

7 (24.14%)

2 (7.41%)

Six Months

7 (22.58%)

6 (20.69%)

9 (33.33%)

Three Months

9 (29.03%)

N = denominator for all percentages

8 (27.59%)

2 (7.41%)
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levels for the three D-tagatose groups after 1, 3 and 6 months
of treatment for the ITT and the EE populations are depicted in
Figures 3A and 3B, respectively. For both analysis populations,
a dose-response trend was observed for the 5.0 g and 7.5 g
D-tagatose doses after 3 months and 6 months of treatment.
Statistically, significant differences between the doses, however,
were not achieved at any of the post-treatment time points (p >
0.5, ANCOVA with baseline as covariate).

Reductions from baseline to six months in mean HbA1c were
observed for the 5.0 g and the 7.5 g dose groups but not for the
2.5 g dose group; i.e., mean baseline and 6-month values were 7.6
± 0.66% and 7.6 ± 1.01%, respectively, for the 2.5 g dose group;
7.4 ± 0.63% and 7.3 ± 0.85%, respectively, for the 5.0 g dose
group; and 7.3 ± 0.60% and 7.1 ± 0.75%, respectively, for the 7.5
g dose group (Figure 3B). These reductions indicate a positive
dose response, although the differences in the observed mean
reductions were not statistically significant between the three
D-tagatose doses.

Effect of D-tagatose on fasting glucose values: For fasting
glucose, only the 7.5 g dosage group exhibited reductions from
baseline at the 3- and 6-month time points in both analyzed
populations (ITT and EE, Figures 4A and 4B, respectively). For
the EE population, baseline and 6-month means in fasting glucose
were 130.4 ± 28.8 mg/dL and 136.3 ± 31.9 mg/dL, respectively,
for the 2.5 g treatment; 129.5 ± 24.0 mg/dL and 131.2 ± 26.3 mg/

Figure 4 Effect of D-tagatose on mean fasting glucose values after 1, 3,
and 6 months of treatment, ITT (A) and EE (B) populations. Data are
presented as the mean ± standard deviation.

dL, respectively, for the 5.0 g treatment; and 136.7 ± 22.8 mg/dL
and 123.1 ± 17.1 mg/dL, respectively, for the 7.5 g treatment (p
= 0.0268) (Figure 4B). For the ITT and the EE populations, the
7.5 g D-tagatose dose group provided a mean reduction in fasting
glucose level after six months of treatment.

Incidence of decreases in fasting glucose levels: Results
indicate a dose-response trend for the incidence of fasting glucose
decreases at 6 months in both the ITT and the EE populations. For
the ITT population, the incidences of fasting glucose decreases
after six months of treatment were 45% (21/47), 39% (18/46),
and 36% (19/52) for the 7.5 g, 5.0 g, and 2.5 g D-tagatose
treatment groups, respectively. For the EE population, the
incidences of glucose decreases were 70% (19/27), 55% (16/29),
and 42% (13/31), respectively. These data are depicted in Figure
5. No statistically significant differences across the treatments (p
> 0.5, logistic regression) were observed for either population at
any of the post treatment time points.

Figure 3 Effect of D-tagatose on mean HbA1c values after 1, 3, and 6
months of treatment, ITT population (A) and EE population (B). Data
are presented as the mean ± standard deviation.
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

Effect of D-tagatose on serum insulin: The mean insulin
levels (µIU/mL) for the three D-tagatose dose groups after 1,
3 and 6 months of treatment and the two analysis populations
are depicted in Figure 6. For both analysis populations, the 7.5
g D-tagatose dose group showed consistent reductions from
the mean baseline insulin level after three and six months of
treatment. For the ITT population (Figure 6A), the 7.5 g D-tagatose
dose group demonstrated a mean baseline insulin level of 8.5
± 8.2 µIU/mL; and after three and six months of treatment the
mean insulin levels for this dose group were 7.3 ± 7.0 µIU/mL
and 5.0 ± 3.6 µIU/mL, respectively. For the EE population (Figure
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6B), the 7.5 g D-tagatose dose group demonstrated a mean
baseline insulin level of 9.1 ± 10.6 µIU/mL; and after three and
six months of treatment the mean insulin levels for this dose
group were 7.2 ± 7.7 µIU/mL and 5.1 ± 3.4 µIU/mL, respectively.
Statistically significant differences between the doses, however,
were not achieved at any of the post-treatment time points (p >
0.5, ANCOVA with baseline as covariate) for either the ITT or the
EE populations.

Figure 5 Effect of D-tagatose on the incidence of fasting blood sugar
(i.e., glucose) decreases after 1, 3, and 6 months of treatment, ITT (A)
and EE (B) populations.

Figure 6 Effect of D-tagatose on mean insulin values after 1, 3, and
6 months of treatment, ITT (A) and EE (b) populations. Data are
presented as the mean ± standard deviation.
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Effect of D-tagatose on lipids: No statistically significant
differences between treatments at any measured time point were
observed for total, LDL, or HDL cholesterol measurements (data
not shown); and all dosages provided some measure of reduction
from mean baseline values at one or more time points. There
was a striking elevation in mean triglyceride level after three
months of treatment with the 5.0 g D-tagatose dose group in both
ITT and EE populations (Figure 7). For the ITT population, the
mean triglyceride concentrations at baseline and three months
for the 5.0 g dose were 181 ± 92.7 mg/dL and 218 ± 149 mg/
dL, respectively; 162 ± 89.8 mg/dL and 179 ± 93.4 mg/dL,
respectively, for the 2.5 g dose; and 179 ± 99.8 mg/dL and 165
± 74.7 mg/dL, respectively, for the 7.5 g dose. The difference
between the treatment groups at the 3-month time point was
statistically significant in the ITT population (p = 0.0296, ANCOVA
with baseline as covariate). Similar results were observed with
the EE population; however the difference between treatments
at three months was not statistically significant with the EE
population.

Effect of D-tagatose on body weight: Mean body weights,
over time, reduced in a dose-response fashion, with the 5.0 g
and the 7.5 g D-tagatose doses providing the greatest reductions
(Figure 8). Mean body weights at baseline, 3-months, and
6-months for the 5.0 g D-tagatose dose group were 165.4 ± 33.0
lbs, 161.5 ± 29.5 lbs, and 161.7 ± 27.5 lbs, respectively; and the
mean body weights for the 7.5 g D-tagatose dose group were 167.4
± 33.0 lbs, 165.1 ± 30.5 lbs, and 160.6 ± 29.3 lbs, respectively. The
mean body weights for the 2.5 g D-tagatose dose group and the
EE population remained within 1 lb of mean baseline weight at
all post baseline time points. There was a statistically significant
difference between the mean weights of the three treatments
at the 3-month time point for the EE population (p = 0.0345,
ANCOVA with baseline as covariate).
Safety results: D-tagatose at all doses was well-tolerated.
None of the reported adverse events were unexpected and
the majority was of a gastrointestinal nature, as expected. The
incidences of all reported events were similar for all treatments.
There were no disparities between the three treatments in any
of the assessed safety parameters. Nearly all reported AEs were
of mild or moderate severity. Severe AEs occurring during the
study are summarized in Table 4. There did not appear to be a
dose-response relationship in terms of AE severity. As expected,
the highest incidences of probably or possibly related AEs
were gastrointestinal disorders. No dose-response trends were
observed for any of the AEs that were assessed as possibly or
probably related to study treatment.

Disposition of subjects: The study disposition of randomized
subjects is provided in Table 5. One hundred and sixty one (161)
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subjects were randomized and analyzed. Of the 161 randomized
subjects, 57/161 (35%) were randomized to the 2.5 g dose
group, 51/161 (32%) were randomized to the 5.0 g dose group,
and 53/161 (33%) were randomized to the 7.5 g dose group.
All treatment groups had a median study medication
compliance of approximately 80%, and full to good compliance
with the study-mandated diet and exercise, as assessed by the
investigator, was 77% to 87% after the first month, 70% to 79%
after three months, and 63% to 74% after six months. Given the
similarity of the treatment groups in terms of demographics,
baseline characteristics, concomitant medication usage, and
compliance with treatment, diet and exercise, the resulting
efficacy and safety analyses were considered reliable for
comparisons between three D-tagatose dose groups.

Figure 7 Effect of D-tagatose on mean triglyceride values after 1, 3,
and 6 months of treatment, ITT (A) and EE (B) populations. Data are
presented as the mean ± standard deviation.

Sixty (60) randomized subjects (37.3%) were withdrawn
before completing the 6-month treatment period. Two
subjects, from each of the dose groups were withdrawn prior
to receiving the first dose of study medication, resulting in a
similar withdrawal rate for each of the three doses. However,
when individual reasons for withdrawal were evaluated, two
interesting dose-response trends were noted: one for subjectinitiated withdrawals and one for withdrawals due to AEs/SAEs
(Table 6).
Subject-initiated withdrawals: Of the randomized subjects,
18.0% (29/161) were withdrawn due to subject request or
lost to follow up. The highest incidence for these two reasons,

Table 4: Incidence of severe adverse events, safety population.

D-tagatose 2.5g D-tagatose 5.0g D-tagatose 7.5g Total
N = 52
N = 46
N = 47
N = 145
n (%)
n (%)
n (%)
n (%)
1
Nausea
1 (2.1%)
(0.7%)
1
Retching
1 (2.1%)
(0.7%)
1
Vomiting
1 (1.9%)
(0.7%)
1
Fatigue
1 (2.2%)
(0.7%)
1
Lethargy
1 (2.2%)
(0.7%)
1
Anxiety
1 (1.9%)
(0.7%)

Table 5: Study Disposition of Randomized Subjects.
Number
Randomized (N)*

Figure 8 Effect of D-tagatose on mean body weight after 1, 3, and
6 months of treatment, ITT (A) and EE (B) populations. Data are
presented as the mean ± standard deviation.
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D-tagatose
2.5g

D-tagatose
5.0g

D-tagatose
7.5g

Total

57

51

53

161

n (%)

n (%)

Received ≥ 1 Dose

55 (96.5%)

49 (96.1%)

Withdrawn

22 (38.6%)

19 (37.3%)

Completed Study†

35 (61.4%)

32 (62.7%)

n (%)

n (%)

155
(96.3%)
101
34 (64.2%)
(62.7%)
60
19 (35.8%)
(37.3%)
51 (96.2%)

*Denominator for all percentages.
†Completed study through the end of the 6-month treatment period
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Table 6: Reasons for Withdraw, Randomized Subjects.
Reason for Withdrawal

Subject Request

Lost to Follow-up

AE/SAE

Protocol Deviation

Termination by Sponsor

Other

Total Withdrawn

D-tagatose 2.5g
N = 57
n (%)

D-tagatose 5.0g
N = 51
n (%)

D-tagatose 7.5g
N = 53
n (%)

Total
N = 161
n (%)

3 (5.3%)

5 (9.8%)

10 (18.9%)

18 (11.2%)

2 (3.9%)

1 (1.9%)

8 (5.0%)

3 (5.3%)

5 (8.8%)

3 (5.9%)

3 (5.3%)

2 (3.9%)*

6 (10.5%)†

7 (13.7%)

2 (3.5%)

22 (38.6%)

0 (0.0%)

19 (37.3%)

5 (9.4%)

2 (3.8%)

0 (0.0%)

1 (1.9%)

19 (35.8%)

11 (6.8%)
7 (4.3%)

2 (1.2%)

14 (8.7%)

60 (37.3%)

N = Randomized subjects; denominator for all percentages
*One randomized subject in this dose group had a recorded reason for withdrawal of “screen failure” and was therefore tabulated with those
withdrawn for a protocol deviation
†One randomized subject in this dose group had no reason for withdrawal specified on the CRF and was therefore tabulated with “Other”

combined, was with the 7.5 g dose group; i.e., 6/57 (10.5%) in
the 2.5 g dose group, 8/51 (15.7%) in the 5.0 g dose group, and
15/53 (28.3%) in the 7.5 g dose group (Table 6). These data
suggest that as the dosage increased so did the drop-outs due to
“subject request” and “lost to follow-up,” combined (i.e., subjectinitiated withdrawals). This observation is supported by the fact
that, when the two reasons (subject request and lost to follow-up)
were analyzed separately, each of the responses also indicated a
positive dose-response. These results all appear to indicate that
as the dosage increased, so did the incidence of subject-initiated
withdrawals.
Withdrawals due to AEs/SAEs: The incidence of
withdrawals due to AEs and SAEs for all dose groups combined
was 8/161 (5.0%) with what appears to be an inverse doseresponse relationship; i.e., as the dosage increased the incidence
of withdrawals due to AEs decreased. The highest incidence
of withdrawals due to AEs was in the 2.5 g dose group (5/57,
8.8%) and the lowest incidence of withdrawals due to AEs was
in the 7.5 g group (1/53, 1.9%) (Table 6). Withdrawals due to
protocol deviations were less than 5% for all doses, combined.
The individual dose groups all had similar incidences, ranging
from approximately 4% to approximately 5%.

DISCUSSION

This dose-ranging trial was conducted to evaluate the effect of
three doses of D-tagatose (2.5 g, 5.0 g, and 7.5 g), taken three times
daily over a period of six months, on various glycemic control
measures and safety parameters in type 2 diabetic patients. In
this trial, the 5.0 g TID dose of D-tagatose was assumed (based on
previous trials [7]) to be a minimally effective dose in reducing
HbA1c, a primary measurement of glycemic control. The 2.5 g tid
dose of D-tagatose (which served as a nominal-effect comparator)
and the 7.5 g tid dose were selected to bracket the 5.0 g tid dosage
level.
The efficacy parameters selected for evaluation in this
trial are all common measures of glycemic control for diabetic
patients: HbA1c, fasting glucose levels, lipid parameters, blood
insulin levels, and body weight. The primary efficacy parameter
selected for this trial was a dichotomous variable: the treatment
success as measured by a reduction from baseline HbA1c by at
J Endocrinol Diabetes Obes 2(4): 1057 (2014)

least 0.5 units after six months of treatment (i.e., 0.5% reduction
in HbA1c after six months of treatment). Dichotomous variables,
by nature, are not the most sensitive metric by which to assess
treatment differences; nevertheless, a treatment difference was
noted in that 12/47 (26%) of the 7.5 g D-tagatose dose group
(ITT population) and 9/27 (33%) EE population in the dose
groups met the endpoint (Tables 2 and 3). For both populations,
of the three studied dosages, the 7.5 g D-tagatose dose exhibited
the greatest incidence of success, as measured by this parameter.
Interestingly, a dose response was not observed in the primary
endpoint. For the ITT population and the primary endpoint, the
2.5 g and the 5.0 g D-tagatose doses had a success incidences of
10/52 (19%) and 7/46 (15%), respectively and the difference
between the three dosages were not statistically significant.
Similar results for the lower doses were observed with the
EE population. Continuous variables are traditionally more
sensitive in detecting differences between treatments. Mean
HbA1c reductions after six months of treatment within the ITT
population were greatest for the 7.5 g D-tagatose group (Figure
3A). The minimum dosage at which HbA1c reductions were
evident was the 5.0 g tid dosage. The mean baseline and the mean
6-month HbA1c values for the 2.5 g treatment group remained the
same. The differences between the treatment groups in HbA1c
measurements were not statistically significant at any post
treatment time point. Similar results with HbA1c reduction were
observed with the EE population (Figure 3B).

Regarding fasting glucose mean values and mean changes
from baseline over time, a reduction from baseline was observed
only in the 7.5 g D-tagatose dose group, beginning after three
months of treatment with increasing reduction at the 6-month
time point, at which time statistical significance was observed
(Figure 4), thereby supporting the analysis of the primary
endpoint. Additionally, for the EE population, the incidence
rates of subjects achieving any decrease in fasting glucose values
indicated consistent increases throughout the treatment period
for the 7.5 g dose group, although the differences across the
groups was not statistically significant at any time point. This
observation provided further support of the primary endpoint
results. The observed increases and reductions in fasting glucose
levels over time for the 2.5 g and the 5.0 g treatments are most
likely due to the inherent variability of the fasting glucose
parameter.
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Each of the doses had some measure of mean insulin reduction
at one or more post-baseline time points in both analyzed
populations. After six months of treatment, however, only the 5.0
g and the 7.5 g dosages had mean levels that were lower than that
of baseline (Figure 6A). There were no statistically significant
differences between treatments at any of the measured time
points. Similar results were observed with the EE population
(Figure 6B).

No statistically significant difference between treatments
at any measured time point was observed for total, LDL, or
HDL cholesterol measurements; and all dosages provided some
measure of reduction from mean baseline values at one or more
time points. There was a striking elevation in mean triglyceride
level after three months of treatment with the 5.0 g D-tagatose
dose group in both the ITT and the EE populations (Figure 7). This
rise in triglycerides at the 5.0 g dose warrants further research.
Mean body weights, over time, were reduced in a positive
dose-response fashion, with the 5.0 g and the 7.5 g D-tagatose
doses providing the greatest reductions (Figure 8). The mean
body weights for the 2.5 g D-tagatose dose group remained within
1 lb of mean baseline weight at all post baseline time points.
D-tagatose at all doses was well tolerated. None of the
reported adverse events were unexpected and the majority was
of a gastrointestinal nature, as expected. The incidences of all
reported events were similar for all treatments. Finally, there
were no disparities between the three treatments in any of the
assessed safety parameters.

Although not always statistically significant, the high dose
(7.5 g tid of D-tagatose) appeared to provide the greatest efficacy
of the three tested doses in terms of incidence rates achieving
≥ 0.5% decrease in HbA1c, reductions in fasting glucose values,
reductions in lipid parameters, reduction in insulin concentration,
and reduction in body weight. Additionally, it appears that 5.0 g
tid of D-tagatose was the minimally effective dose for providing
reduction in glycemic measures within this type 2 diabetic
population.
Future research might investigate the inverse dose-response
relationships for constipation, nausea, headache, vomiting, and
eructation (Table 6).

CONCLUSIONS

Several points can be concluded from this study designed to
determine the minimum dose of D-tagatose required to

•• D-tagatose at 5.0 g tid was the minimal dose required to
reduce HbA1c.
•• D-tagatose at 7.5 g tid provided the greatest effect in most
measured efficacy parameters.

•• Future research might investigate the elevation of mean
triglycerides with the 5.0 g D-tagatose dose group after
three months of treatment. However, this elevation was
transient and did not appear at the 6 month timepoint.
This elevation was also only observed in the ITT
population. If it were a drug effect, it would also likely
appear in the EE population.
J Endocrinol Diabetes Obes 2(4): 1057 (2014)
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